Fig. 2: Collateral drug resistance in drug-resistant variants of M. tuberculosis is mediated via diverse mechanisms. | Nature Communications

Fig. 2: Collateral drug resistance in drug-resistant variants of M. tuberculosis is mediated via diverse mechanisms.

From: The evolution of antibiotic resistance is associated with collateral drug phenotypes in Mycobacterium tuberculosis

Fig. 2

a–d Dose–response curves for selected drug-resistant variants and the drug-susceptible parent against selected antibiotics (highlighting collateral drug resistance). Strain names and candidate mutations are listed below each dose-response. e, f Relative growth of CRISPRi knockdown and non-targeting control strains against PA824 and CFZ. g, h Minimum bactericidal concentration assays for CRISPRi knockdown and non-targeting strains against CFZ. CFUs were determined at day 0 and at day 10. Inoc = starting inoculum on day 0, DMSO = solvent control. Dose–response curves (a–d) are the results of a single biological replicate from a representative experiment (n > 4 independent experiments). e–h are the mean and range of biological duplicates from a representative experiment (n = 2 independent experiments). a–f The Gompertz model was used to fit growth data. g, h Dashed lines represent the upper and lower limits of detection.

Back to article page